港股異動丨三生製藥漲超14%再創階段新高,2024年營收和淨利潤均超市場預期
繼昨日績後收漲10%後,三生製藥(1530.HK)今日再度走強,盤中一度大漲超14%,報12.4港元,股價創2020年7月以來新高。公司此前公佈業績顯示,2024年營收和淨利潤均超市場預期。公司2024年盈利約20.9億元,升34.9%,每股盈利86分,派末期股息每股25港仙,派息持平。期內收入91億元,升16.5%;毛利率較上年增約1個百分點,至86.06%;經調整的經營性EBITDA約34億元,升22.9%。於去年底,集團研發30項重點產品。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.